Expression of CD95 ligand in melanocytic lesions as a diagnostic marker

British Journal of Dermatology

Volumn 139, Issue 2, 1998, Pages 198-206

  Maeda, A ^a   Aragane, Y ^a   Tezuka, T ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CARCINOGENICITY; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; SKIN BIOPSY;

ANTIGENS, CD95; ANTIGENS, SURFACE; DIAGNOSIS, DIFFERENTIAL; DYSPLASTIC NEVUS SYNDROME; FAS LIGAND PROTEIN; HUMANS; LIGANDS; LYMPHATIC METASTASIS; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEVUS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031816327     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02355.x     Document Type: Article

References (28)

1. Jacobson AS, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-54.
2. Kusiak JW, Izzo JA, Zhao B. Neurodegeneration in Alzheimer disease. Is apoptosis involved? Mol Chem Neuropathol 1996; 28: 152-62.
3. Cohen JJ. Programmed cell death in the immune system. Adv Immunol 1991; 50: 55-85.
4. Ameisen JC. Programmed cell death (apoptosis) and cell survival regulation: relevance to AIDS and cancer. AIDS 1994; 8: 1197-213.
5. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26.
6. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-7.
7. Barr PJ, Temei LD. Apoptosis and its role in human diseases. Biotechnol NY 1994; 12: 487-93.
8. Carson DA, Ribeiri JM. Apoptosis and diseases. Lancet 1993; 341: 1251-4.
9. Schall TJ, Lewis M, Koller KJ et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61: 361-70.
10. Ito N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-43.
11. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78.
12. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
13. Bellgrau D, Gold D, Selawry H et al. A role for CD95 ligand in preventing graft rejection. Nature 1995: 377: 630-2.
14. Griffith TS, Brunner T, Fletcher SM et al. Fas-ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
15. Hahne M, Rimoldi D, Schroeter M et al. Melanoma cell expression of Fas (APO-1/CD95) ligand: implication for tumor immune escape. Science 1996; 274: 1363-6.
16. Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705-15.
17. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-8.
18. Gown AM, Vogel AM, Hoak DH et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986; 123: 195-203.
19. Viard I, Limat A, Schroeter M et al. Expression of Fas ligand on human keratinocytes in vitro and in vivo. J Invest Dermatol 1997; 108: 569.
20. Yamamura K, Mishima Y. Antigen dynamics in melanocytic and nevocystic melanoma oncogenesis: anti-ganglioside and anti-ras p21 antibodies as markers of tumor progression. J Invest Dermatol 1990; 94: 174-82.
21. Elder DE, Murphy GF. Malignant tumors (melanomas and related lesions). In: Atlas of Tumor Pathology; Melanocystic Tumors of the Skin, 3rd edn, Vol. 2. Armed Forces Institute of Pathology, 1990; 103-205.
22. Clark WH, Elder DE, Guerry D et al. Model predicting survival in stage I melanomas based on tumor progression. J Natl Cancer Inst 1989; 81: 1893-904.
23. Seline PC, Norris DA, Horikawa T et al. Expression of E and P-cadherin by melanoma cells decreases in progressive melanomas and following ultraviolet radiation. J Invest Dermatol 1996; 106: 1320-4.
24. Harwood CA, Green MA, Cook MG. CD44 expression in melanocytic lesions: a marker of malignant progression? Br J Dermatol 1996; 135: 867-82.
25. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990; 9: 101-12.
26. Natali P, Nicortra MR, Cavaliere R et al. Differential expression of intercellular adhesion molecule ICAM-1 in primary and metastatic melanoma lesions. Cancer Res 1990; 50: 1271-8.
27. Mortarini R, Anichini A. From adhesion to signalling: roles of integrins in the biology of human melanomas. Melanoma Res 1993; 3: 87-97.
28. Kapur RP, Bigler SA, Skelly M, Gown AM. Anti-melanoma monoclonal antibody HMB45 identifies an oncofetal glycoconjugate associated with immature melanosomes. J Histochem Cytochem 1992; 40: 207-12.